Patent FR974945A successfully refreshed from Google Patents.
Patent US4839342A successfully refreshed from Google Patents.
US4839342A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of increasing tear production by topical administration of cyclosporin
Assignee: University of Georgia Research Foundation Inc
•
Filing: 1987-09-03
•
Granted: 1989-06-13
•
Expires: 2007-09-03
Abstract
Abstract The present invention provides a method of treating an aqueous-deficient dry eye state in a patient suffering therefrom, which method includes the step of administering cyclosporin topically to the patient's eye. The cyclosporin is administered as a solution, suspension or ointment in a pharmaceutically acceptable excipient.
Inventors
- 👤 Renee Kaswan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 12:04
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/04; A61K38/12; A61K38/13; A61K9/00; A61K9/0012; A61K9/0048
Claims Analysis
Total Claims: 19
Claim 1
Independent Claim
21 words
A method for enhancing or restoring lacrimal gland tearing comprising topically administering cyclosporin to the eye in a pharmaceutically acceptable vehicle.
Claim 2
Independent Claim
21 words
A method for enhancing or restoring lacrimal gland tearing comprising topically administering cyclosporin to the eye in a pharmaceutically acceptable vehicle.
Claim 3
Dependent Claim
26 words
The method of claim 1 for increasing tear production in a tear-deficient eye comprising topically administering a therapeutically effective amount of a cyclosporin to said eye.
Claim 4
Dependent Claim
29 words
The method of claim 2 wherein said cyclosporin is administered as a solution, suspension or ointment comprising 0.01 to 50 weight percent of cyclosporin in a pharmaceutically acceptable excipient.
Claim 5
Dependent Claim
19 words
The method of claim 3 wherein said cyclosporin is administered in an amount of 0.1 to 20 weight percent.
Claim 6
Dependent Claim
35 words
The method of claim 3 wherein the pharmaceutically acceptable excipient is olive oil, arachis oil, castor oil, polyoxyethylated castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, an alcohol, liposome, silicone fluid or a mixture thereof.
Claim 7
Dependent Claim
11 words
The method of claim 2, wherein said cyclosporin is Cyclosporin A.
Claim 8
Dependent Claim
38 words
The method of claim 2 for increasing tear production in an eye of a patient suffering from an autoimmune dysfunction of the lacrimal glands comprising administering a therapeutically effective amount of a cyclosporin topically to the patient's eye.
Claim 9
Dependent Claim
29 words
The method of claim 2 for treating keratoconjunctivitis sicca in a patient comprising the step of administering a therapeutically effective amount of a cyclosporin topically to the patient's eye.
Claim 10
Dependent Claim
42 words
The method of claim 1 for treating a disorder caused by immune activity in a lacrimal gland of a patient comprising the step of topically administering to the patient's eye a therapeutically effective amount of a cyclosporin to enhance or restore tearing.
Claim 11
Dependent Claim
29 words
The method of claim 9 wherein said cyclosporin is administered as a solution, suspension or ointment comprising 0.01 to 50 weight percent of cyclosporin in a pharmaceutically acceptable excipient.
Claim 12
Dependent Claim
19 words
The method of claim 10 wherein said cyclosporin is administered in an amount of 0.1 to 20 weight percent.
Claim 13
Dependent Claim
35 words
The method of claim 10 wherein the pharmaceutically acceptable excipient is olive oil, arachis oil, castor oil, polyoxyethylated castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, an alcohol, liposome, silicone fluid or a mixture thereof.
Claim 14
Dependent Claim
11 words
The method of claim 9, wherein said cyclosporin is Cyclosporin A.
Claim 15
Dependent Claim
36 words
The method of claim 1 for treating a disorder exacerbated by deficient tear production in a patient comprising topically administering a therapeutically effective amount of a cyclosporin to the patient's eye to enhance or restore tearing.
Claim 16
Dependent Claim
29 words
The method of claim 14 wherein said cyclosporin is administered as a solution, suspension or ointment comprising 0.01 to 50 weight percent of cyclosporin in a pharmaceutically acceptable excipient.
Claim 17
Dependent Claim
19 words
The method of claim 15 wherein said cyclosporin is administered in an amount of 0.1 to 20 weight percent.
Claim 18
Dependent Claim
35 words
The method of claim 15 wherein the pharmaceutically acceptable excipient is olive oil, arachis oil, castor oil, polyoxyethylated castor oil, mineral oil, petroleum jelly, dimethyl sulphoxide, an alcohol, liposome, silicone fluid or a mixture thereof.
Claim 19
Dependent Claim
11 words
The method of claim 14, wherein said cyclosporin is Cyclosporin A.
References Cited (Backward Citations)
US4210581A
Cited
US4108985A
Cited
US4117118A
Cited
US4220641A
Cited
US4289851A
Cited
US4388307A
Cited
US4215199A
Cited
US4220657A
Cited
US4288431A
Cited
US4396542A
Cited
US4554351A
Cited
US4384996A
Cited
US4452818A
Cited
WO1984004681A1
Cited
WO1985001875A1
Cited
US4639434A
Cited
US4681754A
Cited
WO1986003966A1
Cited
US4703033A
Cited
US4649047A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-06-12 | 1992-12-12 | 1993-06-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-06-12 | 1996-12-12 | 1997-06-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-06-12 | 2000-12-12 | 2001-06-13 | $7700.00 | Window Closed / Lapsed |